You have reached the maximum number of Guideline views for today. By creating a free account, you can double your number of complimentary daily views.
To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.
Publication Date: December 1, 2016
Last Updated: March 14, 2022
PMRT for patients With T1-2 tumors with one to three positive axillary lymph nodes who undergo ALND
The panel unanimously agreed that the available evidence shows that PMRT reduces the risks of LRF, any recurrence, and breast cancer mortality for patients with T1-2 breast cancer with one to three positive axillary nodes. (EB, H, S)
American Society for Radiation Oncology
American Society of Clinical Oncology
Society of Surgical Oncology
To continue viewing this pocket guide, please purchase it.